Teva Pharmaceutical Industries Ltd (TEVJF) Revenue (2009 - 2026)

Teva Pharmaceutical Industries' (TEVJF) quarterly Revenue came in at $4.1 billion in Q2 2026, down 0.81% YoY from $4.2 billion in Q2 2025, and up 4.02% on a QoQ basis from $4.0 billion in Q1 2026.

Teva Pharmaceutical Industries Ltd (TEVJF) Revenue (2009 - 2026) Analysis & Trends

Teva Pharmaceutical Industries (TEVJF) has 18 years of Revenue data on file, last reported at $4.1 billion in Q2 2026.

  • Quarterly Revenue fell 0.81% year-over-year to $4.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $17.3 billion (up 13.18% YoY) and the FY2025 annual result came in at $17.3 billion, up 4.32% from the prior year.
  • Revenue advanced to $4.1 billion in Q2 2026, from $4.0 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $4.7 billion in Q4 2025 to a low of $2.9 billion in Q4 2024.
  • A 5-year average of $4.0 billion and a median of $3.9 billion in 2022 frame the typical range for Revenue.
  • Annual changes were most pronounced in 2024 — Revenue plunged 34.93% — and 2025, when it jumped 62.45%.
  • Tracing TEVJF's Revenue over 5 years: stood at $3.9 billion in 2022, then rose by 14.75% to $4.5 billion in 2023, then sank by 34.93% to $2.9 billion in 2024, then surged by 62.45% to $4.7 billion in 2025, then declined by 12.08% to $4.1 billion in 2026.
  • The last three Revenue figures came in at $4.1 billion (Q2 2026), $4.0 billion (Q1 2026), and $4.7 billion (Q4 2025), per Business Quant data.

Peer Comparison

Historic Data

Download Data
DateValue
Jun 30, 2026 4.14 Bn
Mar 31, 2026 3.98 Bn
Dec 31, 2025 4.71 Bn
Sep 30, 2025 4.48 Bn
Jun 30, 2025 4.18 Bn
Mar 31, 2025 3.89 Bn
Dec 31, 2024 2.90 Bn
Sep 30, 2024 4.33 Bn
Jun 30, 2024 4.16 Bn
Mar 31, 2024 3.82 Bn
Dec 31, 2023 4.46 Bn
Sep 30, 2023 3.85 Bn
Jun 30, 2023 3.88 Bn
Mar 31, 2023 3.66 Bn
Dec 31, 2022 3.88 Bn
Sep 30, 2022 3.60 Bn
Jun 30, 2022 3.79 Bn
Mar 31, 2022 3.66 Bn
Dec 31, 2021 4.10 Bn
Sep 30, 2021 3.89 Bn